Dapagliflozin results in more patients with improved or resolved MASH without worsening of fibrosis, improved fibrosis without worsening of MASH.

A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

FRIDAY, June 6, 2025 (HealthDay News) — A repurposed diabetes drug can be an effective tool against fatty liver disease, a ...

A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

A diabetes drug, dapagliflozin, has shown promise in treating fatty liver disease by reducing liver fat and scarring, ...

An SGLT2 inhibitor helped improve metabolic dysfunction-associated steatohepatitis (MASH) in people with or without type 2 ...

SAN DIEGO — Dapagliflozin provides significant benefits in the treatment of chronic kidney disease (CKD) even when initiated in patients with the most severe stages of the disease who are ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...

Citation: Dapagliflozin found to be safe and effective in elderly patients with heart failure undergoing valve replacement (2025, March 31) retrieved 31 May 2025 from https://medicalxpress.com ...